NYSE
$20.33▲ 0.42%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $64.92BShares out 31.900M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
27- 9.16Overnight26.09.16 10:124Ownership#●●●
TAKEDA PHARMACEUTICAL CO LTD
Lauren Rusckowski, an executive at Takeda Pharmaceutical, has filed a report regarding an insider transaction. The filing details the change in beneficial ownership of securities that occurred on September 14, 2026.…more
$20.33+0.42%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.14Pre-market26.09.14 19:256-KKey event
TAKEDA PHARMACEUTICAL CO LTD
Takeda Pharmaceutical announced that the U.S. FDA has accepted its New Drug Application (NDA) for zasocitinib, a treatment for moderate-to-severe plaque psoriasis, under Priority Review. Supported by Phase 3 clinical data demonstrating rapid skin clearance, a final regulatory decision is expected in the first quarter of 2027.…more
$20.33+0.42%vs prev closeView filingShare - 9.10Pre-market26.09.10 21:00144Ownership
TAKEDA PHARMACEUTICAL CO LTD
Lauren Rusckowski, an insider at Takeda Pharmaceutical, has filed an SEC Form 144 to report a proposed sale of company securities. This filing serves as a standard notification of an insider's plan to dispose of shares.…more
$20.33+0.42%vs prev closeView filingShare
26 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.23 20:33Bullish#●●●#●●●#●●●
Takeda's Gastric Cancer Drug Meets Phase 3 Endpoints
Takeda's investigational cancer therapy met its dual primary endpoints in a Phase 3 study, demonstrating significant improvements in overall and progression-free survival for advanced gastric cancer patients. The positive results support upcoming regulatory filings and the potential for expanded global development.…more
$20.33+0.42%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 6d agoPre-market26.10.19 18:53
●●●●●●●● ●●●●● ●●●●●●
Takeda announced Phase 4 VERDICT trial results showing that ENTYVIO treatment significantly reduced the risk of ulcerative colitis-related complications by nearly 70%. The data supports a treat-to-target strategy aimed at achieving disease clearance to improve long-term patient outcomes.…more
$20.33+0.42%vs prev closeShareBenzinga - 10.15Overnight26.10.15 16:01
●●●●●●●● ●●●●● ●●●●●●
Takeda has launched its first-in-class orexin agonist, ORZEYFUL, for type 1 narcolepsy in Japan and China. The U.S. launch is scheduled for next month following the completion of DEA scheduling.…more
$20.33+0.42%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report